Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose vs Standard-dose RT in Stage II-III NPC
NCT05304468Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2022
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 3, randomised trial in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 2 years. Started May 2022; status: active, not recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05304468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304468.